Figure 4
Figure 4. Induction of LMP-1 expression by IL-4, but not IL-13, in EBV-carrying BL and EBV-infected tonsillar B cells. (A) The expression of IL-4R-α in the type I (cl.148, cl.59, cl.216) and the type III (cl.99, cl.176) Mutu clones as assessed by fluorescence-activated cell sorting analysis. On the histogram plots the shaded areas represent the background fluorescence of the control antibody-stained cells, whereas the solid black lines denote the specific staining. The mean fluorescence intensity of the specific staining is indicated on the plots. (B) Immunoblot analysis of total cell extracts of the Mutu I cl.148, cl.59, and cl.216 cells treated with 50 ng/mL IL-4 or IL-13 (24 hours), using LMP-1 and β-actin antibodies. (C) Expression of LMP-1 and EBNA-2 in total cell lysates prepared from the Daudi, P3HR1 and Jijoye M13 cells were treated with IL-4 or IL-13 (50 ng/mL, 24 hours). (D) The expression of IgM, CD83, intercellular adhesion molecule 1 (ICAM-1), human leukocyte antigen (HLA) cl.I, and CD10 in the IL-4–treated (20 ng/mL, 3 days) Jijoye M13 cells as assessed by fluorescence-activated cell sorting analysis. On the histogram plots the shaded areas represent the background fluorescence of the control antibody-stained cells, whereas the solid black lines denote the specific staining. The mean fluorescence intensity of the specific staining and the percentage of the positively stained cells are indicated on the plots. (E) Immunoblot analysis of total cell extracts of the Daudi and P3HR1 after coculture with L cells (control) or CD40L-transfected L cells for 72 hours probed with LMP-1 and β-actin antibodies. (F) Expression of LMP-1 in total cell lysates prepared from the Daudi cells treated with L cells, CD40L-L cells, or CD40L-L cells plus IL-4 or IL-10 (50 ng/mL) for 24 or 48 hours. (G) Expression of EBNA-2, LMP-1, and β-actin in total cell lysates prepared from tonsillar B cells infected with the P3HR1 EBV strain and treated with L cells, CD40L-L cells, L cells plus IL-4 (50 ng/mL), or CD40L-L cells plus IL-4 (50 ng/mL) for 96 hours.

Induction of LMP-1 expression by IL-4, but not IL-13, in EBV-carrying BL and EBV-infected tonsillar B cells. (A) The expression of IL-4R-α in the type I (cl.148, cl.59, cl.216) and the type III (cl.99, cl.176) Mutu clones as assessed by fluorescence-activated cell sorting analysis. On the histogram plots the shaded areas represent the background fluorescence of the control antibody-stained cells, whereas the solid black lines denote the specific staining. The mean fluorescence intensity of the specific staining is indicated on the plots. (B) Immunoblot analysis of total cell extracts of the Mutu I cl.148, cl.59, and cl.216 cells treated with 50 ng/mL IL-4 or IL-13 (24 hours), using LMP-1 and β-actin antibodies. (C) Expression of LMP-1 and EBNA-2 in total cell lysates prepared from the Daudi, P3HR1 and Jijoye M13 cells were treated with IL-4 or IL-13 (50 ng/mL, 24 hours). (D) The expression of IgM, CD83, intercellular adhesion molecule 1 (ICAM-1), human leukocyte antigen (HLA) cl.I, and CD10 in the IL-4–treated (20 ng/mL, 3 days) Jijoye M13 cells as assessed by fluorescence-activated cell sorting analysis. On the histogram plots the shaded areas represent the background fluorescence of the control antibody-stained cells, whereas the solid black lines denote the specific staining. The mean fluorescence intensity of the specific staining and the percentage of the positively stained cells are indicated on the plots. (E) Immunoblot analysis of total cell extracts of the Daudi and P3HR1 after coculture with L cells (control) or CD40L-transfected L cells for 72 hours probed with LMP-1 and β-actin antibodies. (F) Expression of LMP-1 in total cell lysates prepared from the Daudi cells treated with L cells, CD40L-L cells, or CD40L-L cells plus IL-4 or IL-10 (50 ng/mL) for 24 or 48 hours. (G) Expression of EBNA-2, LMP-1, and β-actin in total cell lysates prepared from tonsillar B cells infected with the P3HR1 EBV strain and treated with L cells, CD40L-L cells, L cells plus IL-4 (50 ng/mL), or CD40L-L cells plus IL-4 (50 ng/mL) for 96 hours.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal